Wright, who participated in the Vuity clinical trial, would put the drops in her eyes in the morning, and she found the effect to kick in the moment she got to work. McDonald’s says that on average, it should start working within 15 minutes. âI could see on my computer without struggling or needing glasses, and it lasted the entire working day,â Wright reports. She says she hasn’t experienced any negative side effects. Vuity reports that users may experience temporary issues when switching focus between near and far objects.
When developing the drops, the company found that participants achieved a “gain of three or more lines reading a near vision chart without losing more than one line in a far vision chart by day 30, three hours. after administration. “
âWe know a lot about the active compound pilocarpine. It has been used in higher concentrations and it is very safe, âsays McDonald. She adds that the drops can be used with contact lenses, but like all eye medications, users should wait 15 minutes after application before inserting the lenses. If you are using other eye drops, wait five minutes between applications.
Steven Plotycia, MD, an ophthalmologist affiliated with Mount Sinai Medical Center in New York City, warns that the drops may not work for all people with presbyopia. âThe ideal patient for these drops are people in their 40s and 50s who don’t want to wear reading glasses. The age group is old enough to have developed presbyopia, but young enough not to have started to develop cataracts, âhe explains. Cataracts are lenses that have started to turn yellow, limiting the amount of light that enters, making vision darker. Since Vuity works by constricting the iris, limiting the amount of light that reaches the lens, patients with cataracts will find that the drops make their vision even darker. They would have a hard time driving at night or in other low light situations.
âThe importance of this FDA approval is enormous. Eyeglasses, contact lenses, and surgery are traditional treatments, but for a variety of reasons do not work well for all patients. Having a new treatment option in the form of eye drops for presbyopia is a welcome addition to our arsenal against this universal age-related near vision condition that affects virtually everyone over 40, âsaid said Christopher Starr, MD, clinical spokesperson for the AAO.
Nine similar eye drops for presbyopia are in development and may be available in the future.
Beth Levine is a health writer whose work has appeared in O: The Oprah Magazine, Woman’s Day, Good Housekeeping, Reader’s Book and much more.